-
BIO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Bio-Rad Laboratories (BIO)
Company Profile
Quarter (USD) | Sep 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm | 412.19 mm |
Cash burn (monthly) | (no burn) | 4.36 mm | (no burn) | 6.11 mm | 3.67 mm | (no burn) |
Cash used (since last report) | n/a | 12.17 mm | n/a | 17.05 mm | 10.24 mm | n/a |
Cash remaining | n/a | 400.02 mm | n/a | 395.13 mm | 401.95 mm | n/a |
Runway (months of cash) | n/a | 91.8 | n/a | 64.7 | 109.6 | n/a |
13F holders | Current |
---|---|
Total holders | 235 |
Opened positions | 59 |
Closed positions | 244 |
Increased positions | 54 |
Reduced positions | 85 |
13F shares | Current |
---|---|
Total value | 1.83 tn |
Total shares | 7.58 mm |
Total puts | 37.40 k |
Total calls | 23.20 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
STT State Street | 859.89 k | $234.84 bn |
Van Eck Associates | 659.22 k | $180.04 mm |
Select Equity | 649.52 k | $177.39 bn |
Earnest Partners | 606.79 k | $165.72 bn |
BAC Bank of America | 441.88 k | $120.68 bn |
Ninety One UK | 387.31 k | $105.78 bn |
Southeastern Asset Management | 325.01 k | $88.76 bn |
Westfield Capital Management | 243.19 k | $66.42 bn |
Norges Bank | 226.57 k | $61.88 bn |
MS Morgan Stanley | 217.02 k | $59.27 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Oct 24 | Jonathan P. DiVincenzo | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 7,478 | 0.00 | 7,478 |
20 Oct 24 | Sedat Evran | Bio-Rad A Common Stock | Payment of exercise | Dispose F | No | No | 346.37 | 335 | 116.03 k | 853.14 |
20 Oct 24 | Sedat Evran | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,044 | 0.00 | 1,188.14 |
20 Oct 24 | Sedat Evran | RSU Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 0 | 1,044 | 0.00 | 3,132 |
6 Sep 24 | James Barry | RSU Bio-Rad A Common Stock | Grant | Acquire A | No | No | 0 | 4,224 | 0.00 | 4,224 |
6 Sep 24 | Last Andrew J. | Bio-Rad A Common Stock | Sell | Dispose S | No | No | 329.9384 | 3,000 | 989.82 k | 7,559.45 |
6 Sep 24 | Last Andrew J. | Bio-Rad A Common Stock | Option exercise | Acquire M | No | No | 299.24 | 3,000 | 897.72 k | 10,559.45 |
6 Sep 24 | Last Andrew J. | NQSO Bio-Rad A Common Stock | Option exercise | Dispose M | No | No | 299.24 | 3,000 | 897.72 k | 0 |